Floatz Rating
CCC48/100
Confidence
Indicative
Sponsor
Mustang Bio
Modality
UNKNOWN
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05360238CT.gov Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLL | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Indicative
Detailed axis rationale is planned and will be published soon.
Same indication · Waldenstrom Macroglobulinemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| mb-106 (this asset) | Mustang Bio | P1/2 | CCC · 48 |
| Etoposide | Fred Hutchinson Cancer Center | P2 | BBB |
| Cyclophosphamide | Institute of Hematology & Blood Diseases Hospital, China | P2 | BBB |
| Fludarabine | Institute of Hematology & Blood Diseases Hospital, China | P3 | BBB |
| Prednisone | BeOne Medicines | P2 | BBB |
| Adriamycin | BeOne Medicines | P2 | BBB |
| Romidepsin | Mayo Clinic | P2 | BB |
| Bortezomib | Seoul National University Hospital | P2 | BB |
| Cediranib | National Cancer Institute (NCI) | P2 | BB |
+42 more in the Waldenstrom Macroglobulinemia cohort
Other indications for mb-106
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Follicular Lymphoma | — | P1/2 | CCC · 48 |
| Mantle Cell Lymphoma | — | P1/2 | CCC · 48 |
| Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | — | P1/2 | CCC · 48 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. mb-106 in Waldenstrom Macroglobulinemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/mb-106-waldenstrom-macroglobulinemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →